Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin in Schizophrenia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above~* Diagnosis of schizophrenia.~* Clinically stable antipsychotic regimen for the last 3 months~* A total score of 80 or greater at baseline on the Positive and Negative Syndrome Scale~* Competent and willing to provide written, informed consent~Exclusion Criteria:~* History of substance dependence within the past 2 months~* Existing relevant physical health problems: such as uncontrolled cardiovascular disease and impaired liver/ renal function~* History of diabetes~* History of hepatic or biliary diseases / biliary obstruction~* A serious suicide/homicide risk in the opinion of the investigator~* Known allergy to linagliptin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Linagliptin daily

Based on this trial design, predict the completion outcome and termination type (if applicable).